Table 3 Subgroup analysis of OS

PVI

Without PVI

4

OS^a

0.81

0.63–1.03

32%

4

1y-OS

1.01

0.96–1.07

60%

4

3y-OS

1.08

0.99–1.18

10%

3

5y-OS

0.98

0.72–1.34

52%

With PVI

3

OS^a

0.43

0.19–0.95

73%

3

1y-OS

1.49

0.81–2.75

79%

3

3y-OS

1.94

1.31–2.87

47%

3

5y-OS

1.97

1.02–3.79

31%

Chemotherapy

Cisplatin based

7

OS^a

0.78

0.56–1.00

0%

7

1y-OS

1.10

0.99–1.21

76%

7

3y-OS

1.26

1.04–1.54

76%

5

5y-OS

1.08

0.85–1.38

44%

Interferon + 5-FU

2

OS^a

0.20

0.05–0.35

1%

2

1y-OS

1.81

0.67–4.91

88%

2

3y-OS

2.55

0.95–6.88

61%

2

5y-OS

5.40

1.74–16.77

0%

Oxaliplatin based

2

OS^a

0.60

0.36–0.84

0%

2

1y-OS

1.03

0.98–1.09

0%

2

3y-OS

1.17

0.90–1.51

49%

1

5y-OS

1.71

0.84–3.47

/

MVI

With MVI

5

OS^a

0.68

0.50–0.92

0%

5

1y-OS

1.09

0.99–1.21

75%

5

3y-OS

1.12

1.03–1.22

0%

3

5y-OS

1.17

0.97–1.42

27%